Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Janux Therapeutics (JANX) Non-Current Deffered Revenue (2020 - 2023)

Janux Therapeutics (JANX) has disclosed Non-Current Deffered Revenue for 4 consecutive years, with $307000.0 as the latest value for Q2 2023.

  • On a quarterly basis, Non-Current Deffered Revenue fell 94.2% to $307000.0 in Q2 2023 year-over-year; TTM through Jun 2023 was $307000.0, a 94.2% decrease, with the full-year FY2022 number at $2.2 million, up 217.29% from a year prior.
  • Non-Current Deffered Revenue was $307000.0 for Q2 2023 at Janux Therapeutics, down from $1.4 million in the prior quarter.
  • In the past five years, Non-Current Deffered Revenue ranged from a high of $6.0 million in Q4 2020 to a low of $307000.0 in Q2 2023.
  • A 4-year average of $2.7 million and a median of $2.2 million in 2022 define the central range for Non-Current Deffered Revenue.
  • Peak YoY movement for Non-Current Deffered Revenue: surged 217.29% in 2022, then plummeted 94.2% in 2023.
  • Janux Therapeutics' Non-Current Deffered Revenue stood at $6.0 million in 2020, then crashed by 88.43% to $700000.0 in 2021, then soared by 217.29% to $2.2 million in 2022, then tumbled by 86.18% to $307000.0 in 2023.
  • Per Business Quant, the three most recent readings for JANX's Non-Current Deffered Revenue are $307000.0 (Q2 2023), $1.4 million (Q1 2023), and $2.2 million (Q4 2022).